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Abstract
Background:  Though Dnmt1 is considered the primary maintenance methyltransferase and
Dnmt3a and Dnmt3b are considered de novo methyltransferases in mammals, these three enzymes
may work together in maintaining as well as establishing DNA methylation patterns. It has been
proposed that Dnmt1 may carry out de novo methylation at sites in the genome with transient
single-stranded regions, such as replication origins, and then spread methylation from these
nucleation sites in vivo, even though such activity has not been reported.
Results: In this study, we show that Dnmt3a does not act on single-stranded substrates in vitro,
indicating that Dnmt3a is not likely to initiate DNA methylation at such proposed nucleation sites.
Dnmt3a shows similar methylation activity on unmethylated and hemimethylated duplex DNA,
though with some substrate preference. Unlike Dnmt1, pre-existing cytosine methylation at CpG
sites or non-CpG sites does not stimulate Dnmt3a activity in vitro and in vivo.
Conclusion: The fact that Dnmt3a does not act on single stranded DNA and is not stimulated by
pre-existing cytosine methylation indicates that the de novo methylation activity of Dnmt3a is quite
different from that of Dnmt1. These findings are consistent with a model in which Dnmt3a initiates
methylation on one of the DNA strands of duplex DNA, and these hemimethylated sites then
stimulate Dnmt1 activity for further methylation.
Background
DNA cytosine-5-methyltransferases (Dnmts) catalyze the
methyl transfer from S-adenosyl-L-methionine to the
cytosine in CpG dinucleotides. Four active DNA methyl-
transferases, Dnmt1, Dnmt2, Dnmt3a, and Dnmt3b, have
been reported in mammals. These four enzymes contain
highly conserved DNA methyltransferase motifs; how-
ever, genetic and biochemical studies have suggested func-
tional differences between them. Dnmt1 is considered a
maintenance DNA methyltransferase, though some de
novo methylation activity has been described in vitro [1].
Dnmt3a and Dnmt3b are generally regarded as de novo
DNA methyltransferases, even though it has been pro-
posed that these enzymes may play a role in the mainte-
nance of methylation in ES cells [2]. While the biological
role of Dnmt2 remains unknown, it has been reported to
methylate DNA at a very low level, and it may be involved
in non-CpG methylation [3-6].
De novo methylation mostly occurs during embryonic
development and plays an important role in genomic
imprinting, X-inactivation, and transposon suppression
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in mammals. De novo methylation has been described to
occur frequently in cancer [for a review, see [7]] and at
sites of integrated exogenous DNA [8]. It has been pro-
posed that de novo methyltransferases may participate in
the maintenance of methylation based on the findings
that Dnmt3a and/or Dnmt3b may play roles in restoring
methylation at sites missed by Dnmt1 during replication
in ES cells [2]. A Dnmt1-deficient cancer cell line showed
little loss of DNA methylation, suggesting that the de
novo methyltransferases can maintain a high level of
DNA methylation in the absence of Dnmt1 in neoplastic
cells [9]. A more dramatic loss of DNA methylation was
observed when Dnmt1 and Dnmt3b were both absent
from that cell line, suggesting the possible cooperation
between these two enzymes [10]. Another study using
antisense and RNAi strategies suggested that Dnmt1 is
responsible for global and CpG island methylation in can-
cer cells [11]. These studies raise the possibility that
Dnmt1 and the two de novo methyltransferases may work
together in maintaining, as well as establishing, DNA
methylation patterns.
Dnmt3a has been shown to have biochemical characteris-
tics different than Dnmt1. Dnmt3a shows no preference
for hemimethylated over fully unmethylated DNA sub-
strates, whereas Dnmt1 has a strong preference for hemi-
methylated DNA [12,13]. Dnmt1 has no known
preference other than CpG sites in vitro [14], whereas
Dnmt3a appears to prefer CpG sites flanked by pyrimi-
dines in vitro [15] and shows less specificity for CpG sites
than Dnmt1 both in vitro and in vivo [13,16]. Dnmt3a
generates asymmetrical methylation pattern on two DNA
strands in vitro [15]. These differences reflect the methyl-
ation maintenance function of Dnmt1 and de novo meth-
ylation function of Dnmt3a.
It has been reported that pre-existing cytosine methyla-
tion at CpG as well as at non-CpG sites can stimulate de
novo methylation activity of native and recombinant
Dnmt1 on single-stranded oligonucleotides in vitro
[1,17]. It has been hypothesized that single-stranded DNA
formed during replication or repair might serve as a nucle-
ation site for de novo methylation by Dnmt1 [17]. Puri-
fied murine Dnmt1 overexpressed in E. coli also showed
increased de novo methylation activity when pre-existing
cytosine methylation was present on double-stranded oli-
gonucleotide substrates [18]. In another study, introduc-
tion of random CpG methylation into plasmid DNA
stimulated methylation activity of DNA methyltrans-
ferases partially-purified from human placenta and
murine liver [19]. A more recent study showed that fully
methylated oligonucleotides can also stimulate Dnmt1 de
novo methylation activity in trans [20]. These studies
demonstrate that pre-existing cytosine methylation on
oligonucleotides as well as on plasmids can stimulate the
de novo methylation activity of Dnmt1 in vitro, even
though this activity has not been confirmed in vivo. This
stimulation may be due to the allosteric activation of the
catalytic domain by the binding of Dnmt1 to methylated
DNA [20]. In our previous studies [21-23], de novo meth-
ylation of the episome by endogenous Dnmt1 has not
been detected in human cells regardless of the methyla-
tion status of the episome (CpG methylation at HhaI or
HpaII sites, or non-CpG methylation at Dcm sites of the
plasmid).
It is clear that Dnmt3a is not stimulated by pre-existing
cytosine methylation at CpG sites on only one of the DNA
strands because it does not prefer hemimethylated DNA
over fully unmethylated DNA. While Dnmt3a does not
appear to be stimulated by methylation at HpaII sites on
a 310 bp DNA fragment [24], extensive testing has not
been carried out. One study showed stimulation of
Dnmt3a by hemimethylated CCG and fully methylated
CWG; no stimulation by fully methylated CCG was
detected [25]. It is curious that Dnmt3a is not stimulated
by hemimethylated CpG, fully methylated CpG, and fully
methylated CCG, but it is stimulated by hemimethylated
CCG and fully methylated CWG in vitro [25]. In this
study, we carried out experiments to determine whether
Dnmt3a has similar de novo methylation activity on sin-
gle-stranded substrates and whether it can be stimulated
by pre-existing cytosine methylation, as is the case for
Dnmt1.
Results
Dnmt3a has substrate preferences and does not act on 
single-stranded DNA substrates
The activity of murine Dnmt3a purified from human cells
overexpressing this enzyme was tested in an in vitro meth-
ylation assay with in vitro 3H-incorporation using fully
unmethylated, hemimethylated, and fully methylated 30
bp or 122 bp oligonucleotide substrates. All reactions
were carried out in duplicate with no protein and no DNA
controls, and all experiments were done multiple times.
The no protein controls routinely showed a very low level
of 3H counts; therefore, the level of radioactivity detected
in the no DNA control was treated as background and
subtracted from reactions with DNA substrates. Dnmt1
was used as a control in similar reactions. Consistent with
previous reports [12,24], Dnmt1 is strongly stimulated by
hemimethylated substrates showing approximately a 13-
fold higher activity on these substrates than on fully
unmethylated DNA and showed nearly no activity on
fully methylated DNA (Fig. 1A). Also consistent with the
lack of in vitro site preference reported previously [14],
virtually no difference in Dnmt1 activity between the 30
bp and the 122 bp substrates was detected (Fig. 1A). This
validates the assay and the substrates used.BMC Biochemistry 2005, 6:6 http://www.biomedcentral.com/1471-2091/6/6
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Consistent with previous reports [12,13], Dnmt3a
showed a very low activity on all of the 30 bp substrates,
though the highest activity was detected with fully
unmethylated DNA (UM); and nearly no activity was
detected with fully methylated substrate (DM) (Fig. 1B). A
Dnmt3a catalytic mutant [15] showed background levels
of radioactivity, confirming the activity of Dnmt3a (data
not shown). In contrast, Dnmt3a showed a 20-fold
increase in activity on unmethylated 122 bp substrates
over the unmethylated 30 bp substrate (UM, Fig. 1B).
While near background activity was detected on fully
methylated substrates (DM), Dnmt3a displayed the
In vitro methylation of oligonucleotides by DNA methyltransferases Figure 1
In vitro methylation of oligonucleotides by DNA methyltransferases. A) Duplex 30-mer and 122-mer DNA sub-
strates with hemimethylated top strand (HMTop), hemimethylated bottom strand (HMBot), both strands methylated (DM), 
and fully unmethylated (UM) were used in the in vitro 3H-incorporation assay (counts per minute, CPM) to test the activity of 
purified Dnmt1. B) Duplex 30-mer and 122-mer DNA substrates with hemimethylated top strand (HMTop), hemimethylated 
bottom strand (HMBot), both strands methylated (DM), and fully unmethylated (UM) were used in the in vitro 3H-incorpora-
tion assay (counts per minute, CPM) to test the activity of purified Dnmt3a. C) The single-stranded 122-mer DNA substrates, 
unmethylated top strand (SSTop), unmethylated bottom strand (SSBot), methylated top strand (SMTop), and methylated bot-
tom strand (SMBot), were used to assay Dnmt1 activity in vitro. D) Single-stranded 122-mer DNA substrates, unmethylated 
top strand (SSTop), unmethylated bottom strand (SSBot), methylated top strand (SMTop), and methylated bottom strand 
(SMBot), were used to assay Dnmt3a activity in vitro.
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highest activity on fully unmethylated duplex DNA (UM),
and its activity on hemimethylated substrates (HMTop
and HMBot) was two- to three-fold lower (Fig. 1B). The
activity of Dnmt3a on hemimethylated and unmethylated
122 bp substrates is comparable when the number of
available unmethylated CpG sites is taken into account.
The 30 bp and the 122 bp oligonucleotide substrates have
3 and 4 CpG sites on each strand, respectively. Therefore,
the difference in Dnmt3a activity is not proportional to
the number of available CpG sites on the 30 bp and the
122 bp substrates. Consistent with our previous findings
[15] and results using several other substrates (data not
shown), these findings suggest that Dnmt3a has substrate
preferences while Dnmt1 does not.
A de novo methylation activity of Dnmt1 has been
described as acting on single-stranded substrates at low
efficiency in vitro [1,17]. We were interested in determin-
ing whether Dnmt3a, with its primary function as a de
novo methyltransferase, can also use single-stranded DNA
as a substrate. In vitro methylation assays were carried out
using unmethylated and methylated single-stranded oli-
gonucleotides as substrates for the analysis of Dnmt1 and
Dnmt3a. Dnmt1 showed moderate activity on unmethyl-
ated single-stranded DNA (Fig. 1C; SSTop and SSBot).
This activity is five-fold lower than its activity on hemi-
methylated double-stranded DNA substrates (compare
with Fig. 1A; HMTop and HMBot) and is two-fold higher
than its activity on fully unmethylated duplex DNA (com-
pare with Fig. 1A; UM). These findings are consistent with
previous reports [1,18]. Unlike Dnmt1, Dnmt3a showed
very little activity on unmethylated single-stranded DNA
substrates (Fig. 1D; SSTop and SSBot) and this activity is
ten-fold lower than its activity on fully unmethylated dou-
ble-stranded DNA (compare with Fig. 1B; UM). Both
enzymes showed near background activity on methylated
single-stranded DNA substrates (SMTop and SMBot in
Fig. 1C and Fig. 1D). These findings clearly indicate that
Dnmt1 has a stronger de novo methylation activity on sin-
gle-stranded DNA substrates than on unmethylated
duplex DNA, and the de novo methylation activity of
Dnmt3a primarily targets duplex DNA substrates with
unmethylated CpG sites and not single-stranded DNA. It
is also clear that the de novo methylation activity of these
two enzymes is quite different in vitro.
Pre-existing cytosine methylation on the plasmid does not 
stimulate methylation activity of Dnmt3a in vitro
Previous work indicated that partially-purified human
and mouse Dnmt1 has a higher level of methylation activ-
ity on partially-methylated plasmids than fully unmethyl-
ated plasmids in vitro [19]. Dnmt3a overproduced in E.
coli  showed no increased activity in vitro when three
HpaII sites were methylated on a 310 bp substrate, while
Dnmt1 showed a 2.9-fold increase in activity, even
though the activity reported was low for Dnmt3a [24].
Another report indicated that hemimethylated CCG can
stimulate Dnmt3a but not Dnmt1; fully methylated CCG
fails to stimulate either enzyme; and fully methylated
CWG can stimulate both enzymes [25]. We were inter-
ested in further testing whether murine Dnmt3a is stimu-
lated by pre-existing cytosine methylation on the plasmid
in vitro. Plasmid DNA is often prepared using Dcm-posi-
tive strains of E. coli; therefore, it carries methylated
cytosines at the internal C of CC(A/T)GG site. For this
experiment, plasmid p220.2 DNA was prepared from a
Dcm-negative strain (the plasmid DNA thus derived is
designated p220.2-Dcm) and from a Dcm-positive strain
(plasmid designated p220.2+Dcm) for comparison. The
p220.0-Dcm DNA was further methylated in vitro using
HhaI (GCGC, bold indicates methylation site) methylase,
HpaII (CCGG) methylase, HaeIII (GGCC) methylase, and
MspI (CCGG) methylase individually. The p220.2+Dcm
DNA was also further methylated in vitro using HhaI
methylase, HpaII methylase, BamHI methylase
(GGATCC), and HaeIII methylase individually. BamHI,
HaeIII, and MspI methylases methylate cytosines at non-
CpG sites, while HhaI and HpaII methylases methylate
cytosines at CpG sites. These in vitro methylated sub-
strates were used in the in vitro methylation assay of
Dnmt3a with p220.2+Dcm and p220.0-Dcm DNA as con-
trols. There is very little difference in the Dnmt3a methyl-
ation activity between plasmid DNA with or without Dcm
methylation, indicating the lack of stimulation by fully
methylated CWG sites. Although there are minor varia-
tions detected for substrates methylated with different
methylases, no stimulation by pre-existing cytosine meth-
ylation was observed (Fig. 2). These findings indicate that
Dnmt3a is not stimulated by pre-existing symmetrical
cytosine methylation at CpG sites or at non-CpG sites on
the plasmid substrates in vitro.
Pre-existing CpG methylation on a minichromosome does 
not lead to increased Dnmt3a methylation at HhaI or 
HpaII sites in human cells
To test whether pre-existing CpG methylation can stimu-
late Dnmt3a activity in vivo, a previously established
assay system was used [22]. It has been described previ-
ously [22], cotransfection of Dnmt3a expression vector
with a target plasmid, such as p220.2, into 293/EBNA1
cells leads to methylation of the target plasmid while no
methylation on the target plasmid was detected when the
target plasmid was transfected alone or with a Dnmt3a
catalytic mutant expression vector into 293/EBNA1 cells.
When the transfected plasmid DNA is digested with a
methylation-sensitive restriction enzyme, such as HhaI or
HpaII, the fraction of the increased size fragments can be
compared to the fully digestable fragments in the same
lane to assess the activity of Dnmt3a on the plasmid. Any
loading variation between lanes does not interfere withBMC Biochemistry 2005, 6:6 http://www.biomedcentral.com/1471-2091/6/6
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Pre-existing cytosine methylation does not stimulate Dnmt3a in vitro Figure 2
Pre-existing cytosine methylation does not stimulate Dnmt3a in vitro. Plasmid DNA extracted from a Dcm-negative 
E. coli strain and a Dcm-positive E. coli strain was used in the in vitro 3H-incorporation methylation assay (CPM). The average 
Dnmt3a activities on each plasmid are summarized in the table above the histogram. Both Dcm+ and Dcm-DNA with no CpG 
methylation (Un-Me), CpG methylation at 32 HhaI sites (meHhaI) or 40 HpaII sites (meHpaII), and non-CpG methylation at 51 
HaeIII sites (meHaeIII) were tested. Dcm+ DNA with non-CpG methylation at a single BamHI site (meBamHI) and Dcm- DNA 
with non-CpG methylation at 40 MspI sites (meMspI) were also tested. ND represents data point not determined.
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this assessment because no comparisons of fragments
across lanes are made. p220.2-Dcm plasmid DNA was
methylated with HhaI methylase, HpaII methylase, HaeIII
methylase, and MspI methylase in vitro before being co-
transfected with the Dnmt3a expression vector into 293/
EBNA1 cells. The unmethylated p220.2-Dcm and
p220.2+Dcm were used as controls in this experiment.
Seven days after transfection, the plasmid DNA was har-
vested using the Hirt method and analyzed by Southern
blotting after restriction digestion. There is no appreciable
difference in Dnmt3a methylation activity on plasmids
with and without Dcm methylation when the methyla-
tion sensitive enzyme HhaI is used to assess DNA methyl-
ation on p220.2 (Fig. 3A, lanes 1 and 2). There is also little
Southern blot analysis of de novo methylation on plasmid DNA with various types of pre-existing cytosine methylation Figure 3
Southern blot analysis of de novo methylation on plasmid DNA with various types of pre-existing cytosine 
methylation. A) Southern hybridization of HhaI-digested plasmid DNA harvested eight days after transfection into human 
cells. Plasmid DNA with no Dcm methylation (p220.2-Dcm) and with Dcm methylation (p220.2+Dcm) showed no detectable 
difference in the amount of methylation acquired at HhaI sites. When p220.2-Dcm DNA is methylated in vitro with HpaII 
methylase (me-HpaII p220.2), HaeIII methylase (me-HaeIII p220.2), or MspI methylase (me-MspI p220.2), and then used in the 
transfection experiment, no detectable difference due to either p220.2+Dcm or p220.2-Dcm was observed. B) Southern 
hybridization of HpaII-digested plasmid DNA harvested eight days after transfection into human cells. No detectable difference 
was observed between p220.2-Dcm, p220.2+Dcm, me-HaeIII p220.2, me-MspI p220.2 and plasmid in vitro methylated with 
HhaI methylase (me-HhaI p220.2).BMC Biochemistry 2005, 6:6 http://www.biomedcentral.com/1471-2091/6/6
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difference in methylation at HhaI sites between HpaII-
methylated, HaeIII-methylated, and MspI-methylated
p220.2-Dcm plasmid DNA versus plasmid DNA without
in vitro methylation (Fig. 3A, lanes 2, 3, 4, and 5). No
apparent differences were detected in Dnmt3a methyla-
tion activity at HpaII sites between unmethylated plasmid
and HhaI-methylated, HaeIII-methylated, and MspI-
methylated plasmid DNA (Fig. 3B). When HhaI, HpaII,
BamHI, and HaeIII methylases were used to methylate
p220.2+Dcm DNA, similar results were observed in the
transfection experiments (data not shown). Similar levels
of Dnmt3a protein was detected at two days after transfec-
tion by Western blot using the Myc antibody in the exper-
iments where Dnmt3a expression was monitored (data
not shown). When the same experiments were carried out
using 3a-5 cells that overexpress murine Dnmt3a, similar
results were seen (data not shown). These results indicate
that pre-existing symmetrical methylation at CpG sites or
non-CpG sites does not stimulate Dnmt3a methylation at
HhaI or HpaII sites in human cells.
Pre-existing CpG methylation at HpaII or HhaI sites on the 
minichromosome does not stimulate Dnmt3a methylation 
at other CpG sites in human cells
To examine whether methylation at CpG sites other than
HhaI or HpaII sites is stimulated by pre-existing cytosine
methylation, sodium bisulfite sequencing of three differ-
ent regions in the EBNA1 gene of the plasmid harvested
from transfected human cells was carried out. The
unmethylated p220.2, HhaI-methylated p220.2, and
HpaII-methylated p220.2 plasmids harvested from trans-
fected cells were regionally sequenced for comparison.
Methylation at the HhaI and the HpaII sites was excluded
from the calculation of methylation because of the pre-
existing methylation at these sites on the HhaI-methylated
and HpaII-methylated plasmids.
Unmethylated p220.2 showed 50.8% methylation in the
EBNA1 region 2, 36.3% methylation in the EBNA1 region
4, and 6.3% methylation in the EBNA1 region 6 (Fig. 4A).
HhaI-methylated plasmid p220.2 had 69.3%, 52.8%, and
5.6% of methylation in EBNA1 regions 2, 4, and 6, respec-
tively (Fig. 4B). Similar levels of methylation (49.4%,
53.8%, and 10.4% in EBNA1 regions 2, 4, and 6, respec-
tively) were found on HpaII-methylated p220.2 (Fig. 4C).
The patterns of methylation in all three regions of the
EBNA1 gene were also similar for these three plasmids
(Fig. 4). Previously, 55.3 % and 10.6% of methylation
were detected in the EBNA1 region 2 and region 6, respec-
tively, in similar experiments [15]. The percentage of over-
all methylation is higher in region 2 of HhaI-methylated
p220.2 than unmethylated and HpaII-methylated p220.2.
The percentage of overall methylation in region 4 is also
higher in both HhaI-methylated and HpaII-methylated
p220.2 than unmethylated p220.2. However, the patterns
of methylation are similar for all plasmids in all three
regions. We reasoned that if preexisting methylation HhaI
or HpaII sites can stimulate Dnmt3a in vivo, a larger frac-
tion of highly methylated molecules should be observed
in the transfected HhaI-methylated and HpaII-methylated
p220.2 plasmid when compared with unmethylated
p220.2. Therefore, the sequenced molecules were sorted
into two groups, a group with more than 50% of the CpG
sites methylated and one with less than 50% of the CpG
sites methylated. A chi-square test was then carried out to
test the hypothesis that there is no significant difference
between the number of molecules in these two groups
from p220.2, HhaI-methylateed-p220.2, and HpaII-
methylated p220.2 plasmids. Fisher's exact test was used
to test the same hypothesis for results from region 6
because no molecules from unmethylated and HhaI-
methylated p220.2 had more than 50% of the CpG sites
methylated. The P values of the statistical tests were 0.17,
0.13, and 0.32 for regions 2, 4, and, 6, respectively (Fig.
4D), indicating that the difference is not significant. The
same tests were carried out for regions 2 and 4 with a dif-
ferent cut-off for the sorting to ensure that this does not
change the outcome. When the sequenced molecules
from region 2 were sorted as one group with 5 to 10 meth-
ylated CpG sites and another group with 0 to 4 methyl-
ated CpG sites, the P value of the chi-square test is 0.37.
When the sequenced molecules from region 4 were sorted
into a group with 4 to 8 methylated CpG sites and a group
with 0 to 3 methylated sites, the P value of the chi-square
test is 0.22. Therefore, the higher level of methylation
observed in the EBNA1 regions 2 and 4 on HhaI-methyl-
ated plasmid and in the EBNA1 regions 2 and 6 on HpaII-
methylated plasmid is considered within normal experi-
mental variation and not due to stimulation of Dnmt3a
by the pre-existing methylation at HhaI of HpaII sites.
These findings indicate that there is no stimulation of
methylation at other CpG sites in human cells when HhaI
or HpaII sites carry pre-existing cytosine methylation. It is
noteworthy that no methylation at non-CpG sites was
detected in all three regions sequenced.
Discussion
It has been described that the de novo methylation activ-
ity of Dnmt1 can act on single-stranded DNA [1,17]. This
leads to the hypothesis that single-stranded DNA formed
during replication or repair might serve as a nucleation
site for de novo methylation [17]. Several studies suggest
that CpG islands may serve as DNA replication origins
[for a review see [26]]. As first described by Baylin in 1986
[27], hypermethylation of CpG islands has been well rec-
ognized to occur in cancer. It is possible that the single-
stranded DNA methylation activity of Dnmt1 targets it to
CpG islands that are DNA replication origins and initiates
de novo methylation in the genome. Since the primary
function of Dnmt3a is de novo methylation, it is impor-BMC Biochemistry 2005, 6:6 http://www.biomedcentral.com/1471-2091/6/6
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Sodium bisulfite sequencing of three different regions of the EBNA1 gene from transfected plasmids Figure 4
Sodium bisulfite sequencing of three different regions of the EBNA1 gene from transfected plasmids. A) Fully 
unmethylated p220.2, B) HhaI methylated p220.2, and C) HpaII methylated p220.2 were harvested eight days after co-transfec-
tion into human cells and sodium bisufite sequenced. Regions 2, 4, and 6 of the EBNA1 gene as designated previously [14] were 
sequenced. There is a single HhaI site in region 2 and region 6, and there are three HpaII sites in region 4 as indicated on the 
top of the CpG sites and designated with a box. The percentage of methylation was calculated by dividing the total number of 
methylation sites detected (excluding methylation found in the HhaI and HpaII sites) by the total number of CpG sites exam-
ined (also excluding the HhaI and the HpaII sites). The white rectangular box indicates the premethylated HhaI and HpaII sites 
on the plasmids. D) Sorting and statistical analysis of the two groups of sequenced molecules from each region. The degrees of 
freedom (df) are equal to 2. Column A represents molecules from unmethylated p220.2, column B represents molecules from 
HhaI-methylated p220.2, and column C represents molecules from HpaII-methylated p220.2.
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tant to know whether Dnmt3a has such an activity. Unlike
Dnmt1, we find here that Dnmt3a does not act on single-
stranded oligonucleotides in vitro. Although one previous
study [28] reported Dnmt3a methylation of single-
stranded oligonucleotide substrates, the conclusion
remains unclear based on the substrate used in that study.
The substrate used in Yokochi and Robertson [28] has 10
CpG sites on an oligomer which is 34 nucleotides in
length and which has GATC on both ends; therefore, it
can form double-stranded regions over substantial
lengths both intra- and inter-molecularly under low salt
and moderately high temperature conditions. In contrast,
the 122 bases oligonucleotide substrate used in this study
does not form CpG pairing either intra- or inter-molecu-
larly based on several oligonucleotide analysis software
packages. Furthermore, no other conformation was
observed when the radioactive-labeled oligonucleotide
was resolved on a native gel either as single-stranded or
double-stranded configuration (data not shown).
In our study, Dnmt3a showed a much higher activity on
the 122 bp double-stranded DNA substrate than on the 30
bp substrate, indicating some form of substrate prefer-
ence. We have tested other substrates ranging from 83 bp
to 130 bp and the substrate length or the potential proces-
sivity of the enzyme is not the basis for these differences
(data not shown), indicating that local DNA sequence is
the basis. These findings suggest functional differences for
the de novo methylation activity of these two enzymes.
Based on our study here, if de novo methylation occurs at
CpG sites within DNA with single-stranded features in
vivo, then Dnmt3a is not likely to be the methyltrans-
ferase responsible for this process. Also, Dnmt3a may pre-
fer certain sequences while Dnmt1 does not discriminate
among its targets.
It has been shown that pre-existing cytosine methylation
can stimulate de novo methylation activity of Dnmt1 in
vitro both in cis and in trans [17-19]. This suggests that
Dnmt1 can be stimulated by hemimethylated DNA as
well as symmetrically methylated DNA. In a previous
study, Dnmt3a overproduced in E. coli showed no
increased activity when three HpaII sites were methylated
on a 310 bp substrate, even though the activity of Dnmt3a
was low [24]. However, another study showed stimula-
tion of Dnmt3a by hemimethylated CCG and fully meth-
ylated CWG [25]. Here, we performed both in vitro and in
vivo testing of whether pre-existing cytosine methylation
can stimulate Dnmt3a, including fully methylated CCG
and CWG sites. We find that Dcm+ plasmid DNA does not
stimulate Dnmt3a activity in vitro when compared with
plasmid DNA without methylation at these Dcm sites,
suggesting the lack of stimulation by methylation at CWG
sites. This finding is at odds with the finding of Kim et al.
[25]. There are several non-CpG sites on the methylated
CWG and CCG substrates used in Kim et al. [25]. It is pos-
sible that CWG methylation does not stimulate CpG
methylation but stimulates a non-CpG methylation activ-
ity in those reactions, since the Dnmt3a used in Kim et al.
was demonstrated to have non-CpG methylation activity
[25]. The Dnmt3a used in our study has no detectable
non-CpG methylation activity; therefore, no increased
activity was observed with pre-existing cytosine methyla-
tion. However, it is intriguing that Dnmt3a is not stimu-
lated by hemimethylated CpG, fully methylated CpG, or
fully methylated CCG, and yet it is stimulated by hemi-
methylated CCG and fully methylated CWG in vitro [25].
Whether this difference is due to the expression of the
enzyme in insect cells versus human cells would need fur-
ther investigation. There is also no stimulation of the
Dnmt3a activity in vitro by cytosine methylation at other
CpG or non-CpG sites on the plasmid with or without
Dcm methylation. These findings indicate a clear differ-
ence between the de novo methylation activity of Dnmt1
and Dnmt3a in vitro.
Transfection experiments also showed that pre-existing
cytosine methylation at CpG sites or non-CpG sites does
not stimulate Dnmt3a to methylate CpGs at HhaI and
HpaII sites on the minichromosome. Sodium bisulfite
sequencing of the transfected minichromosome further
showed that methylation at HhaI or HpaII sites does not
lead to increased methylation at other CpG sites. Methyl-
ation at non-CpG sites by Dnmt3a was not detected in any
of the molecules sequenced, indicating the lack of non-
CpG methylation by Dnmt3a in this particular human
cell line. These findings demonstrate that pre-existing
cytosine methylation does not stimulate Dnmt3a activity
for either CpG or non-CpG methylation in human cells.
It has been proposed that Dnmt1 plays a role in DNA
methylation spreading in mammalian cells [24]. In our
previous transfection experiments using patch-methyl-
ated minichromosomes, no spreading of methylation
from the methylated patch was observed [23]. We also
have not observed de novo methylation on the transfected
minichromosomes with methylation at HhaI or HpaII
sites by bisulfite sequencing (data not shown). These find-
ings indicate the lack of de novo methylation activity on
these minichromosomes without overexpression of
Dnmt3a in human cells. Although it remains unclear
which methyltransferases are involved in methylation
spreading, the fact that Dnmt3a is not stimulated by hem-
imethylated DNA or by symmetrically methylated DNA
strongly suggests that Dnmt3a does not participate in this
process. Consistent with the findings in Fatemi et al [24],
we have found that plasmid DNA premethylated with
Dnmt3a stimulates Dnmt1 activity more than two-fold in
vitro (data not shown). In our previous study, Dnmt3aBMC Biochemistry 2005, 6:6 http://www.biomedcentral.com/1471-2091/6/6
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generates an asymmetrical methylation pattern on the two
DNA strands in vitro [15].
Therefore, it is very likely that one of the processes for de
novo methylation is for Dnmt3a to initiate methylation
on one DNA strand; then this hemimethylated DNA
would lead to the stimulation of Dnmt1 for further meth-
ylation (Fig. 5). This activity of Dnmt1 would be in addi-
tion to its known methylation of hemimethylated sites
after DNA replication (Fig. 5).
Conclusion
In this study, we demonstrated several novel differences
between Dnmt1 and Dnmt3a de novo methylation activ-
ity. Unlike Dnmt1, Dnmt3a produced in human cells has
very little activity on single-stranded DNA in vitro. While
Dnmt1 shows higher de novo methylation activity on sin-
gle-stranded substrates than on unmethylated duplex
DNA, Dnmt3a primarily acts on unmethylated sites on
duplex DNA. Dnmt1 shows no preference for substrates
with different sequence or length, whereas Dnmt3a shows
preference for different substrates. In contrast to Dnmt1,
Dnmt3a is not stimulated by pre-existing cytosine methyl-
ation on plasmids either at CpG sites or non-CpG sites in
vitro. This is the first study demonstrating that pre-existing
cytosine methylation does not stimulate the activity of
Dnmt3a at CpG or non-CpG sites in human cells. The de
novo methylation activity of these two enzymes is clearly
different.
Methods
Oligonucleotide substrates
The 30-mer double-stranded oligonucleotide substrates
used in this study are identical to the ones used in Pard-
han et al [1] and Okano et al [12] with the addition of one
hemimethylated substrate with the CpG methylation on
the anti-parallel DNA strand. The 30-mer oligonucle-
otides were synthesized by Operon. The top strand of the
122-mer substrate, 5'-GATACATATTTGAATGTATTTA-
GAAAAATAAACAAATAGGGGTTC
CGCGCACATTTCCCCGAAAAGTGCCACCT-
GACGTCTAAGAAACCATTATT ATCATGACATTAAC-
CTATAAAAATAGG-3', was derived from the EBNA1
sequence that contains 4 CpG sites. The bottom strand of
the substrate is the complementary sequence of the top
strand. The 122-mer oligonucleotides were synthesized
and purified by the Microchemical Core facility of the
Norris Cancer Center. The double-stranded substrates
Model for one of the de novo methylation processes carried out by Dnmt3a and Dnmt1 Figure 5
Model for one of the de novo methylation processes carried out by Dnmt3a and Dnmt1. Dnmt3a initiates methyl-
ation on one DNA strand at its preferred CpG sites (filled circles). After DNA replication, Dnmt1 methylates the other strand 
(open circles) at these hemimethylated sites. The hemimethylated DNA may also stimulate Dnmt1 for further methylation at 
previous unmethylated CpG sites (open circles indicated with ?).
DNMT1
Dnmt3a methylates its preferred targets
DNA replication
??
? ? ? ?
? ?BMC Biochemistry 2005, 6:6 http://www.biomedcentral.com/1471-2091/6/6
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were generated by adding equimolar amounts of the com-
plementary strands in 10 mM TrisHCl (pH 8.0) and 100
mM NaCl, boiling for 10 min, and slowly cooling in a
bath of 300 ml water at room temperature. The annealing
of the oligonucleotides was checked by PAGE. The hemi-
methylated HMTop substrates were generated using a top
strand oligonucleotide with methyl cytosines at all the
CpG sites and a fully unmethylated bottom strand oligo-
nucleotide. The hemimethylated HMBot substrates were
made with unmethylated top strand and fully methylated
bottom strand oligonucleotides. The fully methylated
substrates (DM) contain methylated top and methylated
bottom strand oligonucleotides. The fully unmethylated
substrates (UM) were generated with unmethylated top
and bottom strand oligonucleotides.
Enzymes and in vitro 3H-incorporation assay
Human Dnmt1 was purchased from New England
Biolabs. The GST-Dnmt3a (GST-3a) and GST-Dnmt3a
mutant (GST-3aMut) fusion proteins were expressed in
293T cells and purified using glutathione-agarose beads as
described previously [15]. In vitro methylation activity of
Dnmt1, Dnmt3a, and Dnmt3a mutant was measured by
3H-incorporation assay. In vitro methylation was carried
out for Dnmt3a and the Dnmt3a mutant in a 20 ul reac-
tion with 314 fmol of enzyme in 10 mM TrisHCl (pH
8.0), 1 mM EDTA, 1 mM DTT, and 1.1 uM 3H-AdoMet
(New England Nuclear, 14.7 Ci/mmol) at 37°C overnight
(16 hours). The same assay was carried out for Dnmt1
(New England Biolabs) in a 25 ul reaction with 1.1 uM
3H-AdoMet in the manufacturer's recommended buffer
using 2.5 units of the enzyme. In each reaction, 0.25 pmol
of the duplex substrate or 0.5 pmol of the single-stranded
substrate was used. The in vitro methylation reaction was
treated with Proteinase K at 55°C for 1 h before being
spotted onto the DE-81 filters and washed as described
previously [29]. The radioactivity retained on the air-dried
DE-81 filters was measured by scintillation counting
(Packard Tri Carb 2100TR) with 2 ml of scintillation fluid.
Plasmid and in vitro methylation of plasmid
The plasmid p220.2 [30] was used throughout the study.
Plasmid p220.2 DNA without Dcm methylation, desig-
nated p220.2-Dcm, was prepared from a Dcm-negative
strain, GM127. Plasmid DNA with Dcm methylation, des-
ignated p220.2+Dcm, was prepared from a Dcm-positive
strain, DH10B. The p220.0-Dcm DNA was further meth-
ylated in vitro using HhaI methylase, HpaII methylase,
HaeIII methylase, and MspI methylase individually. The
p220.2+Dcm DNA was further methylated in vitro using
prokaryotic methylase, HhaI methylase, HpaII methylase,
BamHI methylase, or HaeIII methylase individually.
MeHhaI-p220.2 was in vitro methylated at all HhaI sites
using the HhaI-methylase (New England Biolabs) under
the conditions recommended by the manufacturer. MeH-
paII-p220.2 was methylated at HpaII sites according to
the conditions suggested by the manufacturer using the
HpaII methylase (New England Biolabs). Two cytosine
methylases that methylate non-CpG sites, BamHI methy-
lase and HaeIII methylase, were used to generate
meBamHI-p220.2 and meHaeIII-p220.2, respectively.
There are 32 HhaI sites, 40 HpaII sites, a single BamHI
site, 51 HaeIII sites, and 40 MspI sites on p220.2. After
methylation, DNA was extracted with phenol-chloroform
followed by ethanol precipitation. The methylation status
was verified by restriction enzyme digestion using the
appropriate enzyme for the specific methylase used.
Cell lines and transfection
The 293/EBNA1 and 3a-5 cells were used in this study.
The 3a-5 cells were derived by integrating a Dnmt3a
expression construct into the 293/EBNA1 cells [22].
Throughout the study, the calcium phosphate transfection
method was used to introduce DNA into the human cell
line. In some experiments, wildtype or mutant Dnmt3a
expression vector [22], pMT3aMyc and pMT3aMut, was
cotransfected with the assay plasmid into 293/EBNA1
cells.
DNA recovery and analysis
Plasmid DNA was harvested from the cells by the Hirt
method [31] when the cells reached confluence after
transfection. A small fraction of the cells was re-seeded for
later harvests. The plasmid DNA harvested from the trans-
fected cells was digested with HhaI or HpaII enzyme, frac-
tionated on 1% agarose gel, and analyzed by Southern
blot analysis using the entire plasmid as a probe.
Bisulfite genomic sequencing and statistical analysis
Bisulfite genomic sequencing was carried out as described
previously [32] with minor modifications. Three different
regions, regions 2, 4, and 6, of the EBNA1 gene, on the
plasmid p220.2 were amplified and ligated into the
TOPO TA cloning vector (Invitrogen). The locations of
these three regions as well as primer sequences and PCR
conditions have been described previously [14]. Both
strands of each clone were sequenced using the EXCEL II
sequencing kit (Epicentre) and analyzed on the Li-Cor
4200 sequencer. Bisulfite sequencing results for each of
the three regions from p220.2, HhaI-methylated p220.2,
and HpaII-methylated p220.2 were compared. Molecules
were sorted into two groups: one with more than 50% of
the CpG sites methylated and one with less than 50% of
the CpG sites methylated. A chi-square test was carried out
to test the hypothesis that there is no significant difference
between the number of molecules in each of the two
groups observed from p220.2, HhaI-methylateed-p220.2,
and HpaII-methylated p220.2 plasmids. A Fisher's exact
test was used to test the same hypothesis for results fromPublish with BioMed Central    and   every 
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region 6 because nearly all of the molecules had less than
50% of the CpG sites methylated.
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